Doximity (NYSE:DOCS) Director Sells $375,235.00 in Stock

Doximity, Inc. (NYSE:DOCS) Director Timothy Cabral sold 10,721 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $35.00, for a total value of $375,235.00. Following the sale, the director owned 8,084 shares of the company’s stock, valued at $282,940. The trade was a 57.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Doximity Stock Up 1.6%

Shares of DOCS stock traded up $0.52 during trading hours on Monday, reaching $33.02. The company’s stock had a trading volume of 3,072,633 shares, compared to its average volume of 3,886,933. The firm’s 50 day simple moving average is $29.09 and its 200-day simple moving average is $25.51. The company has a market capitalization of $5.89 billion, a price-to-earnings ratio of 45.87, a PEG ratio of 25.43 and a beta of 1.29. Doximity, Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $55.96.

Doximity (NYSE:DOCS) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.17. Doximity had a return on equity of 15.80% and a net margin of 21.12%. The company had revenue of $174.54 million for the quarter. During the same quarter in the previous year, the business posted $0.45 EPS. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Sell-side analysts predict that Doximity, Inc. will post 0.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Barclays lifted their price target on shares of Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a report on Friday, August 21st. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price objective on shares of Doximity in a research note on Friday. Canaccord Genuity Group increased their price objective on shares of Doximity from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Friday. BMO Capital Markets restated a “market perform” rating and issued a $30.00 target price on shares of Doximity in a research report on Friday, August 7th. Finally, Royal Bank Of Canada boosted their target price on shares of Doximity from $28.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday. Eight analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $30.45.

Institutional Trading of Doximity

A number of hedge funds have recently made changes to their positions in DOCS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Doximity during the 3rd quarter worth approximately $45,000. Versant Capital Management Inc increased its position in Doximity by 1,176.9% in the 3rd quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock valued at $52,000 after acquiring an additional 1,683 shares during the period. Nisa Investment Advisors LLC increased its position in Doximity by 59.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock valued at $53,000 after acquiring an additional 695 shares during the period. Bessemer Group Inc. increased its position in Doximity by 79.8% in the 3rd quarter. Bessemer Group Inc. now owns 1,910 shares of the company’s stock valued at $54,000 after acquiring an additional 848 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Doximity by 111.0% during the first quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after acquiring an additional 1,347 shares during the last quarter. 87.19% of the stock is owned by institutional investors and hedge funds.

Key Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Analysts raised Doximity price targets to $40 and $34, while Needham reiterated its Buy rating—signals of continued optimism despite recent concerns. Price target raised to $40 Price target raised to $34 Needham Buy rating reiterated
• Neutral Sentiment: Truist maintained a Hold rating, reflecting a more cautious view alongside the bullish analyst calls. Truist keeps Hold rating
• Negative Sentiment: Several law firms publicized the same securities class action, with a November 16, 2026 lead-plaintiff deadline for investors who acquired shares from August 8, 2024, through May 13, 2026. The complaint alleges Doximity misrepresented revenue growth and market share and failed to disclose slowing sales, contracting net income, and changes in pharmaceutical customers’ advertising budgets. These remain allegations, but the litigation could create reputational and legal overhang. Shareholder alert and allegations

About Doximity

Doximity, Inc operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals.

The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.

Founded in 2010, Doximity primarily serves the U.S.